<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459678</url>
  </required_header>
  <id_info>
    <org_study_id>13-3884</org_study_id>
    <nct_id>NCT02459678</nct_id>
  </id_info>
  <brief_title>ART Readiness in HIV-infected Pregnant Women</brief_title>
  <official_title>ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the readiness of HIV-infected pregnant women in Zambia to
      initiate, adhere to, and be retained in care under the Ministry of Health's Option B+ policy.
      Under a 3-phased research study the investigators will: (1) conduct formative research
      regarding readiness to start lifelong ART in the pregnant population; (2) translate the
      results of formative research into a readiness assessment tool and an enhanced adherence
      package for pregnant women eligible for Option B+ and (3) conduct an individual randomized
      trial of the enhanced adherence package.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is qualitative and quantitative research exploring the issues of patient readiness to
      initiate lifelong ART among HIV-infected pregnant women, as well as ART adherence and
      retention in HIV care and treatment during pregnancy and after delivery.

      The objectives of Phase 1 of the study are as follows:

        -  To identify common themes about patient readiness for ART initiation in the days and
           weeks following ART eligibility in the context of pregnancy

        -  To learn about strategies that HIV-infected women and partners of reproductive-age women
           believe will assist with daily adherence to triple-drug ART and retention in care during
           pregnancy and after delivery

      The objectives of Phase 2 of the study are as follows:

        -  To develop a screening instrument for assessing readiness of ART initiation during
           pregnancy

        -  To pilot the ART readiness assessment tool and evaluate its acceptability and
           feasibility through qualitative research

        -  To design a combination intervention that systematically addresses barriers to patient
           readiness and in so doing, may shorten time from HIV diagnosis to ART initiation and
           increase rates of ART adherence and retention in care in the short term

      The objectives of Phase 3 of the study are as follows:

        -  To evaluate an enhanced adherence package for improving timely ART initiation and
           retention in care, defined by attending follow-up ART visit(s), at 30 days after ART
           eligibility and by maternal HIV viral levels at time of delivery

        -  To determine the accuracy of the screening instrument in predicting ART readiness by
           looking at early ART adherence and retention

        -  To obtain early data about virologic response in pregnancy and postnatal period among
           HIV-infected women on Option B+

        -  To obtain data about 6-week and 6-month MTCT rates of HIV among HIV-infected women on
           Option B+

        -  To obtain data about renal function in pregnancy and postnatal period among HIV-infected
           women on Option B+, given that tenofovir is first-line in Zambia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women who both initiate ART and are retained in care</measure>
    <time_frame>Within 30 days of eligibilty to begin ART under Option B+ policy</time_frame>
    <description>ART eligibility in the setting of Option B+ will generally be either the date of HIV diagnosis for pregnant women newly diagnosed with HIV infection during their antenatal care visit or the date of their first antenatal care visit for known HIV-infected pregnant women who are not already on ART</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV virologic suppression at time of delivery</measure>
    <time_frame>Time of delivery</time_frame>
    <description>Outcome of virologic suppression at delivery will be analyzed for differences between the SOC arm and intervention arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from ART eligibility to ART initiation</measure>
    <time_frame>Time from ART eligibility to initiation from enrollment until 6 months post-partum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV transmission from mother to infant</measure>
    <time_frame>At 6 weeks and 6 months of life</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">526</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced adherence package</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Adherence Package</intervention_name>
    <description>The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.</description>
    <arm_group_label>Enhanced adherence package</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The criteria vary by study phase as follows:

        Phase 1

        Inclusion Criteria:

          -  HIV-infected pregnant women not yet on ART OR

          -  HIV-infected pregnant or postnatal women on ART OR

          -  Partners of women who were recently or are currently pregnant

        Exclusion Criteria:

          -  Less than 18 years old

          -  Known history of mental illness

        Phase 2

        Inclusion Criteria:

          -  HIV-infected pregnant or postnatal women on ART who piloted tested the readiness
             assessment tool OR

          -  Health care workers involved in provision of PMTCT and/or ART services at health
             facility who have pilot tested the readiness assessment tool

        Phase 3

        Inclusion Criteria:

          -  Pregnant

          -  HIV-infected

          -  Never previously initiated or was on ART for her own health

          -  Able to provide informed consent

          -  Willing to undergo all study tests and procedures and be followed until 6 months
             post-partum

        Exclusion criteria:

          -  Less than 18 years old

          -  Known intrauterine fetal demise

          -  Known history of mental illness

          -  Does not intend to receive antenatal care, labour and delivery care, and postnatal
             care at the government health facilities of Lusaka District
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mwangelwa Mubiana, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Infectious Disease Research in Zambia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Chi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J Vinikoor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Infectious Disease Research in Zambia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mwangelwa Mubiana-Mbewe, MBChB</last_name>
    <email>mwangelwa.mbewe@cidrz.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael J Vinikoor, MD</last_name>
    <email>michael.vinikoor@cidrz.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mwangelwa Mubiana-Mbewe</last_name>
      <email>mwangelwa.mbewe@cidrz.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Millennium Development Goals Progress Report. 2011, Ministry of Finance and National Planning, UNDP: Lusaka.</citation>
  </reference>
  <reference>
    <citation>National HIV/AIDS/STIs/TB Council, 2009 HIV Epidemiological Projections Report. 2009: Zambia.</citation>
  </reference>
  <reference>
    <citation>Republic of Zambia Ministry of Health, National Protocol Guidelines Integrated Prevention of Mother-to-Child Transmission of HIV, Directorate of Public Health and Research, Editor. 2010, Ministry of Health: Lusaka, Zambia.</citation>
  </reference>
  <reference>
    <citation>Government of the Republic of Zambia, National Protocol Guidelines Integrated Prevention of Mother-to-Child Transmission of HIV/AIDS, M.o. Health, Editor. 2008: Lusaka.</citation>
  </reference>
  <reference>
    <citation>Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach: 2010 Version. Geneva: World Health Organization; 2010.</citation>
    <PMID>26180894</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Impact of an innovative approach to prevent mother-to-child transmission of HIV--Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51.</citation>
    <PMID>23446514</PMID>
  </reference>
  <reference>
    <citation>World Health Organization, Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, in HIV/AIDS Programme. 2012: Geneva.</citation>
  </reference>
  <reference>
    <citation>Government of the Republic of Zambia, Lifelong Antiretroviral Drugs (ARV's) for all HIV positive Pregnant Women in Zambia, M.o. Health, Editor. 2013: Lusaka.</citation>
  </reference>
  <reference>
    <citation>Government of the Republic of Zambia, Adult and Adolescent Antiretroviral Therapy Protocols, M.o. Health, Editor. 2010: Lusaka.</citation>
  </reference>
  <reference>
    <citation>Shaffer N, Abrams EJ, Becquet R. Option B+ for prevention of mother-to-child transmission of HIV in resource-constrained settings: great promise but some early caution. AIDS. 2014 Feb 20;28(4):599-601. doi: 10.1097/QAD.0000000000000144.</citation>
    <PMID>24469000</PMID>
  </reference>
  <reference>
    <citation>Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, Chirwa Z, Ng'ambi W, Bakali A, Phiri S, Myer L, Valeri F, Zwahlen M, Wandeler G, Keiser O. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS. 2014 Feb 20;28(4):589-598. doi: 10.1097/QAD.0000000000000143.</citation>
    <PMID>24468999</PMID>
  </reference>
  <reference>
    <citation>UNAIDS. HIV and AIDS estimates 2009. [cited 2011 April 11]; Available from: http://www.unaids.org/en/regionscountries/countries/zambia/.</citation>
  </reference>
  <reference>
    <citation>Zambia National HIV/AIDS/STI/TB Council, Zambia HIV Prevention Response and Modes of Transmission Analysis. 2009.</citation>
  </reference>
  <reference>
    <citation>Mazimba C, C.W., , Kaseba C, Chi B, HIV-related maternal mortality in Lusaka, Zambia: 1993-2004, in 3rd IAS Conference on HIV Pathogenesis and Treatment: Rio de Janeiro, Brazil.</citation>
  </reference>
  <reference>
    <citation>Moodley J, Pattinson RC, Baxter C, Sibeko S, Abdool Karim Q. Strengthening HIV services for pregnant women: an opportunity to reduce maternal mortality rates in Southern Africa/sub-Saharan Africa. BJOG. 2011 Jan;118(2):219-25. doi: 10.1111/j.1471-0528.2010.02726.x. Epub 2010 Sep 24. Review.</citation>
    <PMID>21159120</PMID>
  </reference>
  <reference>
    <citation>McIntyre J. Maternal health and HIV. Reprod Health Matters. 2005 May;13(25):129-35.</citation>
    <PMID>16035606</PMID>
  </reference>
  <reference>
    <citation>Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Kasonde P, Mwiya M, Tsai WY, Thea DM; Zambia Exclusive Breastfeeding Study (ZEBS). Differential effects of early weaning for HIV-free survival of children born to HIV-infected mothers by severity of maternal disease. PLoS One. 2009 Jun 26;4(6):e6059. doi: 10.1371/journal.pone.0006059.</citation>
    <PMID>19557167</PMID>
  </reference>
  <reference>
    <citation>Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Mwiya M, Thea DM. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission. AIDS. 2010 Jun 1;24(9):1374-7.</citation>
    <PMID>20568677</PMID>
  </reference>
  <reference>
    <citation>Sewankambo NK, Gray RH, Ahmad S, Serwadda D, Wabwire-Mangen F, Nalugoda F, Kiwanuka N, Lutalo T, Kigozi G, Li C, Meehan MP, Brahmbatt H, Wawer MJ. Mortality associated with HIV infection in rural Rakai District, Uganda. AIDS. 2000 Oct 20;14(15):2391-400.</citation>
    <PMID>11089628</PMID>
  </reference>
  <reference>
    <citation>Bicego G, Boerma JT, Ronsmans C. The effect of AIDS on maternal mortality in Malawi and Zimbabwe. AIDS. 2002 May 3;16(7):1078-81.</citation>
    <PMID>11953479</PMID>
  </reference>
  <reference>
    <citation>Morgenstern TT, Grimes DE, Grimes RM. Assessment of readiness to initiate antiretroviral therapy. HIV Clin Trials. 2002 Mar-Apr;3(2):168-72.</citation>
    <PMID>11976996</PMID>
  </reference>
  <reference>
    <citation>Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012 Oct 23;26(16):2039-52. doi: 10.1097/QAD.0b013e328359590f. Review.</citation>
    <PMID>22951634</PMID>
  </reference>
  <reference>
    <citation>Weigel R, Hosseinipour MC, Feldacker C, Gareta D, Tweya H, Chiwoko J, Gumulira J, Kalulu M, Mofolo I, Kamanga E, Mwale G, Kadzakumanja A, Jere E, Phiri S. Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi. Trop Med Int Health. 2012 Jun;17(6):751-9. doi: 10.1111/j.1365-3156.2012.02980.x. Epub 2012 Apr 5.</citation>
    <PMID>22487553</PMID>
  </reference>
  <reference>
    <citation>Wagner GJ, Goggin K, Remien RH, Rosen MI, Simoni J, Bangsberg DR, Liu H; MACH14 Investigators. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011 Dec;42(3):352-60. doi: 10.1007/s12160-011-9295-8.</citation>
    <PMID>21818528</PMID>
  </reference>
  <reference>
    <citation>Balfour L, Kowal J, Silverman A, Tasca GA, Angel JB, Macpherson PA, Garber G, Cooper CL, Cameron DW. A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care. 2006 Oct;18(7):830-8.</citation>
    <PMID>16971295</PMID>
  </reference>
  <reference>
    <citation>Tremblay CL, Baril JG, Fletcher D, Kilby D, Macpherson P, Shafran SD, Tyndall MW. Challenges in initiating antiretroviral therapy in 2010. Can J Infect Dis Med Microbiol. 2010 Aug;21 Suppl C:1C-15C.</citation>
    <PMID>23365594</PMID>
  </reference>
  <reference>
    <citation>Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, Bregenzer T, Vernazza P, Jäger H, Spirig R, Battegay M; Swiss HIV Cohort Study. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection. 2005 Aug;33(4):249-56.</citation>
    <PMID>16091895</PMID>
  </reference>
  <reference>
    <citation>Wolff B, Mbonye M, Coutinho A, Amuron B, Nkabala R, Jaffar S, Grosskurth H. High levels of psychosocial readiness for ART in an African population at the onset of treatment. SAHARA J. 2009 Dec;6(4):188-94.</citation>
    <PMID>20485858</PMID>
  </reference>
  <reference>
    <citation>Macdonell KE, Naar-King S, Murphy DA, Parsons JT, Harper GW. Predictors of medication adherence in high risk youth of color living with HIV. J Pediatr Psychol. 2010 Jul;35(6):593-601. doi: 10.1093/jpepsy/jsp080. Epub 2009 Sep 15.</citation>
    <PMID>19755495</PMID>
  </reference>
  <reference>
    <citation>Tessema B, Biadglegne F, Mulu A, Getachew A, Emmrich F, Sack U. Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study. AIDS Res Ther. 2010 Jan 14;7:2. doi: 10.1186/1742-6405-7-2.</citation>
    <PMID>20180959</PMID>
  </reference>
  <reference>
    <citation>Central Statistical Office, Demographic Health Survey. 2007: Lusaka.</citation>
  </reference>
  <reference>
    <citation>Weiss L, French T, Finkelstein R, Waters M, Mukherjee R, Agins B. HIV-related knowledge and adherence to HAART. AIDS Care. 2003 Oct;15(5):673-9.</citation>
    <PMID>12959818</PMID>
  </reference>
  <reference>
    <citation>Johnson MO, Gamarel KE, Dawson Rose C. Changing HIV treatment expectancies: a pilot study. AIDS Care. 2006 Aug;18(6):550-3.</citation>
    <PMID>16831781</PMID>
  </reference>
  <reference>
    <citation>Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):194-201.</citation>
    <PMID>17971712</PMID>
  </reference>
  <reference>
    <citation>Johnson MO, Dilworth SE, Stephens E, Lum PJ, Neilands TB. Expectancy and readiness-based predictors of treatment uptake among the urban poor living with HIV. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):469-71. doi: 10.1097/QAI.0b013e3182365671.</citation>
    <PMID>21926630</PMID>
  </reference>
  <reference>
    <citation>Grimes RM, Grimes DE. Patient readiness to adhere to HAART. J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):364-6. doi: 10.1177/1545109709351240.</citation>
    <PMID>19952288</PMID>
  </reference>
  <reference>
    <citation>Wagner G, Iguchi M, Schneider S, Scott J, Anderson D. Placebo practice trials: a tool to assess and improve adherence readiness. HIV Clin Trials. 2002 Nov-Dec;3(6):475-81.</citation>
    <PMID>12501131</PMID>
  </reference>
  <reference>
    <citation>Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004 May;16(4):501-6.</citation>
    <PMID>15203417</PMID>
  </reference>
  <reference>
    <citation>Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, Melbourne K, Mitty J, Caro JJ. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000 Jul;22(7):858-71.</citation>
    <PMID>10945512</PMID>
  </reference>
  <reference>
    <citation>Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001 Feb;13(2):61-8. Review.</citation>
    <PMID>11930399</PMID>
  </reference>
  <reference>
    <citation>Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, Orrell C, Altice FL, Bangsberg DR, Bartlett JG, Beckwith CG, Dowshen N, Gordon CM, Horn T, Kumar P, Scott JD, Stirratt MJ, Remien RH, Simoni JM, Nachega JB. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012 Jun 5;156(11):817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294. doi: 10.7326/0003-4819-156-11-201206050-00419. Epub 2012 Mar 5.</citation>
    <PMID>22393036</PMID>
  </reference>
  <reference>
    <citation>Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, Garber G, Macpherson PA, Cameron DW. Development and validation of the HIV Medication Readiness Scale. Assessment. 2007 Dec;14(4):408-16.</citation>
    <PMID>17986658</PMID>
  </reference>
  <reference>
    <citation>Grimes RM, Grimes DE. Readiness: the state of the science (or the lack thereof). Curr HIV/AIDS Rep. 2010 Nov;7(4):245-52. doi: 10.1007/s11904-010-0056-2. Review.</citation>
    <PMID>20714831</PMID>
  </reference>
  <reference>
    <citation>Fernández MI, Hosek S, Warren JC, Jacobs RJ, Hernandez N, Martinez J; Adolescent Medicine Trials Network (ATN). Development of an easy to use tool to assess HIV treatment readiness in adolescent clinical care settings. AIDS Care. 2011 Nov;23(11):1492-9. doi: 10.1080/09540121.2011.565020. Epub 2011 Jun 21.</citation>
    <PMID>22022853</PMID>
  </reference>
  <reference>
    <citation>Chi BH, Bolton-Moore C, Holmes CB. Prevention of mother-to-child HIV transmission within the continuum of maternal, newborn, and child health services. Curr Opin HIV AIDS. 2013 Sep;8(5):498-503. doi: 10.1097/COH.0b013e3283637f7a. Review.</citation>
    <PMID>23872611</PMID>
  </reference>
  <reference>
    <citation>Stubbs BA, Micek MA, Pfeiffer JT, Montoya P, Gloyd S. Treatment partners and adherence to HAART in Central Mozambique. AIDS Care. 2009 Nov;21(11):1412-9. doi: 10.1080/09540120902814395.</citation>
    <PMID>20024718</PMID>
  </reference>
  <reference>
    <citation>Cook PF, McCabe MM, Emiliozzi S, Pointer L. Telephone nurse counseling improves HIV medication adherence: an effectiveness study. J Assoc Nurses AIDS Care. 2009 Jul-Aug;20(4):316-25. doi: 10.1016/j.jana.2009.02.008.</citation>
    <PMID>19576548</PMID>
  </reference>
  <reference>
    <citation>Rodrigues R, Shet A, Antony J, Sidney K, Arumugam K, Krishnamurthy S, D'Souza G, DeCosta A. Supporting adherence to antiretroviral therapy with mobile phone reminders: results from a cohort in South India. PLoS One. 2012;7(8):e40723. doi: 10.1371/journal.pone.0040723. Epub 2012 Aug 27.</citation>
    <PMID>22952574</PMID>
  </reference>
  <reference>
    <citation>Seidenberg P, Nicholson S, Schaefer M, Semrau K, Bweupe M, Masese N, Bonawitz R, Chitembo L, Goggin C, Thea DM. Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test results. Bull World Health Organ. 2012 May 1;90(5):348-56. doi: 10.2471/BLT.11.100032.</citation>
    <PMID>22589568</PMID>
  </reference>
  <reference>
    <citation>Webster PD, Sibanyoni M, Malekutu D, Mate KS, Venter WD, Barker PM, Moleko W. Using quality improvement to accelerate highly active antiretroviral treatment coverage in South Africa. BMJ Qual Saf. 2012 Apr;21(4):315-24. doi: 10.1136/bmjqs-2011-000381.</citation>
    <PMID>22438327</PMID>
  </reference>
  <reference>
    <citation>Assefa Y, Kiflie A, Tekle B, Mariam DH, Laga M, Van Damme W. Effectiveness and acceptability of delivery of antiretroviral treatment in health centres by health officers and nurses in Ethiopia. J Health Serv Res Policy. 2012 Jan;17(1):24-9. doi: 10.1258/jhsrp.2011.010135. Epub 2011 Nov 17.</citation>
    <PMID>22096081</PMID>
  </reference>
  <reference>
    <citation>Perez F, Aung KD, Ndoro T, Engelsmann B, Dabis F. Participation of traditional birth attendants in prevention of mother-to-child transmission of HIV services in two rural districts in Zimbabwe: a feasibility study. BMC Public Health. 2008 Dec 5;8:401. doi: 10.1186/1471-2458-8-401.</citation>
    <PMID>19061506</PMID>
  </reference>
  <reference>
    <citation>Borghi J, Ensor T, Somanathan A, Lissner C, Mills A; Lancet Maternal Survival Series steering group. Mobilising financial resources for maternal health. Lancet. 2006 Oct 21;368(9545):1457-65. Review.</citation>
    <PMID>17055948</PMID>
  </reference>
  <reference>
    <citation>Schmidt JO, Ensor T, Hossain A, Khan S. Vouchers as demand side financing instruments for health care: a review of the Bangladesh maternal voucher scheme. Health Policy. 2010 Jul;96(2):98-107. doi: 10.1016/j.healthpol.2010.01.008. Review.</citation>
    <PMID>20138385</PMID>
  </reference>
  <reference>
    <citation>Ekirapa-Kiracho E, Waiswa P, Rahman MH, Makumbi F, Kiwanuka N, Okui O, Rutebemberwa E, Bua J, Mutebi A, Nalwadda G, Serwadda D, Pariyo GW, Peters DH. Increasing access to institutional deliveries using demand and supply side incentives: early results from a quasi-experimental study. BMC Int Health Hum Rights. 2011 Mar 9;11 Suppl 1:S11. doi: 10.1186/1472-698X-11-S1-S11.</citation>
    <PMID>21410998</PMID>
  </reference>
  <reference>
    <citation>Kalembo FW, Zgambo M, Mulaga AN, Yukai D, Ahmed NI. Association between male partner involvement and the uptake of prevention of mother-to-child transmission of HIV (PMTCT) interventions in Mwanza district, Malawi: a retrospective cohort study. PLoS One. 2013 Jun 12;8(6):e66517. doi: 10.1371/journal.pone.0066517. Print 2013.</citation>
    <PMID>23776683</PMID>
  </reference>
  <reference>
    <citation>Myer L, Zulliger R, Bekker LG, Abrams E. Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIV-positive mothers: a cohort study. BMC Pregnancy Childbirth. 2012 Sep 11;12:94. doi: 10.1186/1471-2393-12-94.</citation>
    <PMID>22963318</PMID>
  </reference>
  <reference>
    <citation>Krueger, R. and M. Casey, Focus Groups: A Practical Guide for Applied Research, 3rd edition. 2000, Thousand Oaks: Sage Publications.</citation>
  </reference>
  <reference>
    <citation>Nordqvist O, Södergård B, Tully MP, Sönnerborg A, Lindblad AK. Assessing and achieving readiness to initiate HIV medication. Patient Educ Couns. 2006 Jul;62(1):21-30. Review.</citation>
    <PMID>16766244</PMID>
  </reference>
  <reference>
    <citation>Bernard, H.R., Research Methods in Anthropology. 1995, Walnut Creek Altamira Press 535.</citation>
  </reference>
  <reference>
    <citation>Miles, M. and A. Huberman, Qualitative Data Analysis: An Expanded Sourcebook. 2nd ed. 1994, Thousand Oaks: Sage Publications.</citation>
  </reference>
  <reference>
    <citation>Enriquez M, Lackey NR, O'Connor MC, McKinsey DS. Successful adherence after multiple HIV treatment failures. J Adv Nurs. 2004 Feb;45(4):438-46.</citation>
    <PMID>14756838</PMID>
  </reference>
  <reference>
    <citation>Gerbert B, Bronstone A, Clanon K, Abercrombie P, Bangsberg D. Combination antiretroviral therapy: health care providers confront emerging dilemmas. AIDS Care. 2000 Aug;12(4):409-21.</citation>
    <PMID>11091774</PMID>
  </reference>
  <reference>
    <citation>Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, Chi BH, Stringer JS, Stringer EM. Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):224-8. doi: 10.1097/QAI.0b013e318229147e.</citation>
    <PMID>21709566</PMID>
  </reference>
  <reference>
    <citation>European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007 Jun 15;44(12):1647-56. Epub 2007 May 2.</citation>
    <PMID>17516411</PMID>
  </reference>
  <reference>
    <citation>Naar-King S, Parsons JT, Murphy D, Kolmodin K, Harris DR; ATN 004 Protocol Team. A multisite randomized trial of a motivational intervention targeting multiple risks in youth living with HIV: initial effects on motivation, self-efficacy, and depression. J Adolesc Health. 2010 May;46(5):422-8. doi: 10.1016/j.jadohealth.2009.11.198. Epub 2010 Feb 4.</citation>
    <PMID>20413077</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

